Compare AORT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AORT | VCEL |
|---|---|---|
| Founded | 1984 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1993 | 1997 |
| Metric | AORT | VCEL |
|---|---|---|
| Price | $43.48 | $37.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $49.36 | ★ $57.50 |
| AVG Volume (30 Days) | 304.0K | ★ 586.8K |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $422,646,000.00 | $258,716,999.00 |
| Revenue This Year | $15.97 | $17.86 |
| Revenue Next Year | $10.96 | $18.55 |
| P/E Ratio | ★ N/A | $151.65 |
| Revenue Growth | 9.81 | ★ 14.05 |
| 52 Week Low | $21.97 | $29.24 |
| 52 Week High | $48.25 | $63.00 |
| Indicator | AORT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 48.73 |
| Support Level | $41.82 | $35.99 |
| Resistance Level | $45.99 | $41.65 |
| Average True Range (ATR) | 1.38 | 1.75 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 33.07 | 32.12 |
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.